The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

AFL great, turned Cerutty Macro Fund portfolio manager, Chris Judd is with HP Rx founder and managing partner Hashan De Silva for today’s Talk Ya Book.

They discuss CurveBeam AI (ASX:CVB), a company in which Mr De Silva is a director. Mr De Silva holds 565,493 ordinary shares, millions of options and 320,928 indirect shares.

The company’s developed a CT scanning device, called HiRise, that works when a patient is weight-bearing, providing imaging while patients are standing. The images can be done within an orthopaedic centre, and release lower radiation levels.

CurveBeam has a market cap of $36 million and was trading at 16 cents (May 28).

KP Rx invests in a diverse range of biotech, medical device, diagnostic, and health tech companies located predominantly in Australia and New Zealand. It is backed by Karst Peak Capital.

Talk Ya Book was created by Chris Judd in 2019 as a show where fund managers could share their highest conviction investment idea but more importantly showcase their investment framework to the public.

Disclaimer: Juddcorp Pty Ltd ACN 635 629 631 is a corporate authorised representative (CAR) (CAR Number 1300536) of Boutique Capital Pty Ltd ACN 621 697 621 AFSL 508011.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
Australian currency cash

Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M

Mesoblast is back onto investors' radars with good tidings from its sale of Ryoncil, with that…
AI image of a lung cross section

4DX up another 15% on new demo delivery; now boasting $2.5B cap & no revenue

4DMedical has climbed to a lofty valuation just short of $4.80 on Wednesday, bringing the biotech…
The Market Online Video

Almonty Industries crosses the line: From tungsten build to cash-flow reality

CY25 was an exceptionally successful calendar year for Almonty Industries Inc. (ASX: AII).
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Beyond ETFs: Why CY26 demands active stock picking

As the calendar turns toward 2026, most investors will make the exact same resolution they always do: set it, forget it, and trust